



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## **Cais Rhyddid Gwybodaeth / Freedom of Information request** **Ein Cyf / Our Ref: 22-L-028**

Please note that we have provided this information for the 24 month period December 2020 to November 2022.

### **You asked:**

#### **Patients with acute myeloid leukaemia (AML)**

- 1. How many patients have received treatment with venetoclax for AML during the past 24 months? Note: please provide data for the most recent 24-month period available via your prescribing/management system.**

13 patients

- 2. What is the average daily dose (mg) for AML patients receiving venetoclax during the past 24 months?**

132.4mg

- 3. What is the average cycle intensity (days) for AML patients receiving venetoclax during the past 24 months? (e.g., 14-day cycles, 21-day cycles, other length of cycle)**

28 day cycles

- 4. What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months?**

3.8 months

#### **Patients with chronic lymphocytic leukaemia (CLL)**

- 5. Please complete the table below based on the number of patients that have received venetoclax in each of the specified regimens for CLL in the last 24 months.**



**Note:** please provide data for the most recent 24-month period available via your prescribing/management system.

	Treatment regimens		
	Venetoclax + obinutuzumab	Venetoclax+ rituximab	Venetoclax monotherapy
Total number of CLL patients receiving this treatment regimen during the past 24 months	7	<5	<5
Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*	400	400	400
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months	9	8.5	N/A

**\*We would like to understand the average daily dose of venetoclax in CLL patients during maintenance treatment i.e. after the initial 8-week period during which patients would be receiving a titration regimen.**

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**Patients with acute myeloid leukaemia (AML) or chronic lymphocytic leukaemia (CLL)**

**6. Please complete the table below with the average number of venetoclax 10 mg x 14 tablet packs† used per AML or CLL patient receiving each of the specified regimens during the past 24 months.**

	AML treatment regimen	CLL treatment regimens		
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10 mg x 14 tablet packs used per				



<p>patient in each treatment regimen during the past 24 months</p>				
--	--	--	--	--

**There are five different pack sizes of venetoclax available in the UK:**

- **Pack 1: venetoclax 10 mg x 14 tablets**
- **Pack 2: venetoclax 50 mg x 7 tablets**
- **Pack 3: venetoclax 100 mg x 7 tablets**
- **Pack 4: venetoclax 100 mg x 14 tablets**
- **Pack 5: venetoclax 100 mg x 112 tablets**

I can confirm that dispensing information is not held centrally down to diagnosis level. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

**7. Please can you share your prescribing protocol(s) for venetoclax in AML and CLL?**

The Health Board does not hold local prescribing protocols for venetoclax. Prescribing protocols for venetoclax in all haematological cancers are held within the ChemoCare system. Please find attached the Chemocare prescribing protocols for venetoclax used by SBUHB.

